AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026

Core Viewpoint - AIM ImmunoTech Inc. has extended the subscription period for its rights offering until March 3, 2026, to raise funds for the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][2]. Group 1: Rights Offering Details - The subscription period for the rights offering began on February 11, 2026, and all holders must submit a completed subscription rights certificate along with payment by the new deadline [2]. - Subscription rights are non-transferable and must be exercised during the subscription period; once exercised, they cannot be revoked or changed [2]. - AIM has appointed Maxim Group LLC as the dealer-manager for the rights offering, and inquiries can be directed to them for further information [3]. Group 2: Regulatory and Compliance Information - The registration statement for the rights offering was declared effective by the SEC on February 10, 2026, and the related prospectus is available on the SEC's website [4]. - Stockholders as of February 10, 2026, should independently assess whether to exercise their subscription rights based on the company's financial condition and prospects [6]. Group 3: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of Ampligen®, which is a dsRNA and selective TLR3 agonist immuno-modulator showing broad-spectrum activity in clinical trials for late-stage pancreatic cancer [7].